Bristol-Myers Squibb (NY:BMY)

61.15 +0.32 (+0.53%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

93 94 Next >

10 Years Later: 5 Winners in a Thinking World ↗

May 13, 2026

What happens when you actually do the thing most investors only talk about and hold stocks for a full decade?

Via The Motley Fool

2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down

May 13, 2026

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Via StockStory

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

May 12, 2026

From Pacira BioSciences

Via GlobeNewswire

Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?

May 12, 2026

Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, markin...

Via StockStory

Topics Stocks

Bristol Myers Squibb (NYSE:BMY) Q1 2026 Earnings Beat Driven by Growth Portfolio ↗

April 30, 2026

Via Chartmill

Topics Earnings

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗

May 11, 2026

This may be an excellent deal for those focused on the long game.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting ↗

May 10, 2026

Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives,...

Via MarketBeat

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

May 08, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol-Myers Squibb’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 07, 2026

Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed product...

Via StockStory

Topics Earnings

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

May 06, 2026

From Bristol Myers Squibb

Via Business Wire

1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges

May 06, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged...

Via StockStory

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™

May 04, 2026

From Bristol Myers Squibb

Via Business Wire

BMY Q1 Deep Dive: Growth Portfolio, Pipeline Milestones, and Anticipated Late-Stage Readouts

May 01, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill...

Via StockStory

Why Bristol Myers Squibb Stock Rocked the Market Today ↗

April 30, 2026

It scored crushing beats on both revenue and profitability in its first quarter.

Via The Motley Fool

Bristol Myers (BMY) Q1 2026 Earnings Transcript ↗

April 30, 2026

Bristol Myers (BMY) Q1 2026 Earnings Transcript

Via The Motley Fool

Bristol-Myers Squibb (NYSE:BMY) Exceeds Q1 CY2026 Expectations

April 30, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill...

Via StockStory

Bristol Myers Squibb Reports First Quarter Financial Results for 2026

April 30, 2026

From Bristol Myers Squibb

Via Business Wire

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow

April 28, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting earnings this Thursday before market open. Here’s what investors should know. Bri...

Via StockStory

3 Healthcare Stocks That Pay You While You Wait for the Growth ↗

April 27, 2026

It may not seem like it at first, but these dividends are safe.

Via The Motley Fool

Topics Intellectual Property

3 Biotech Stocks That Could Benefit from the Patent Cliff ↗

April 27, 2026

Via MarketBeat

Topics Intellectual Property

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

This pharma stock is cheap for a reason.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb: Low Volatility Meets High Dividend Yield ↗

April 26, 2026

Volatility and dividend yield are important metrics for investors thinking about a long-term buy.

Via The Motley Fool

Topics Intellectual Property

3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery ↗

April 25, 2026

As you wait for stock prices to rebound, these three healthcare companies pay dividends with generous yields.

Via The Motley Fool

Topics Intellectual Property World Trade

April 22, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

April 20, 2026

From Ardelyx, Inc.

Via GlobeNewswire

2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗

April 15, 2026

Recent performances don't tell the whole story.

Via The Motley Fool

J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher

April 15, 2026

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared...

Via MarketMinute

Topics Economy Intellectual Property

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗

April 12, 2026

Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong.

Via The Motley Fool

Topics Intellectual Property

2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap ↗

April 10, 2026

Healthcare never sleeps.

Via The Motley Fool

Topics Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

93 94 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.